te Boekhorst Paul Francis Olivier's Form 4 filing
Immucell Corp (ICCC) · filed Dec 3, 2025
- Accession no.
- 0001437749-25-036794
- Filed
- Dec 3, 2025
- Trade date
- Dec 2-3, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $48.6K. It was filed 1 day after the trade.
This filing was later replaced by the amendment 0001437749-25-036913 (Dec 4, 2025). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| te Boekhorst Paul Francis OlivierCIK 0002095704 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2025 | Common Stock $0.10 par value per share | PPurchaseAcquired | +3,708 | $4.87 | +$18,057.96 | 3,708 | Direct | |
| Dec 3, 2025 | Common Stock $0.10 par value per share | PPurchaseAcquired | +2,556 | $5.00 | +$12,780 | 6,264 | Direct | |
| Dec 3, 2025 | Common Stock $0.10 par value per share | PPurchaseAcquired | +3,521 | $5.04 | +$17,745.84 | 9,785 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.